What is already known on this topic Glucagon-like peptide-1 receptor agonist (GLP-1RA) is a promising drug class that has shown benefits for adults with type 2 diabetes Regulatory authorities have approved several GLP-1RA drugs, and novel drugs are continually emerging, resulting in an urgent need for updated evidence synthesis of the comparative effectiveness of various GLP-1RAs What this study adds Compared with the placebo, all 15 GLP-1RAs had significant effects on glycaemic control, and tirzepatide was the most effective in reducing haemoglobin A 1c and fasting plasma glucose concentrations CagriSema induced the highest weight reduction in adults with type 2 diabetes, followed by tirzepatide and retatrutide Several GLP-1RAs resulted in a significantly higher odds ratio of discontinuation due to adverse events than placebo, raising safety concerns about gastrointestinal adverse events, especially at high doses Web extra
Therefore, one of the most important approaches in melasma management and potentially mitigating its progression is photoprotection
In all these two-layer Nycodenz gradients the parietal cells band at the interface between the Nycodenz solutions
A simple blood panel can identify these gaps, and targeted supplementation often restores energy within 23 weeks
Empower patients to co-create the long-term reset
Tesamorelin is FDA approved as Egrifta for HIV-associated lipodystrophy and as Egrifta SV in an updated formulation
